Systemic therapy of aggressive fibromatosis in children and adolescents: Report of the Cooperative Weichteilsarkom Studiengruppe (CWS)

Treatment algorithms for patients with aggressive fibromatosis (AF) are challenging. There are limited data available about the use of systemic therapy (ST) in pediatric patients with AF.

[1]  P. Meltzer,et al.  Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis). , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Robin L. Jones,et al.  Pazopanib, a promising option for the treatment of aggressive fibromatosis , 2017, Anti-cancer drugs.

[3]  L. Mariani,et al.  Long-term Efficacy of Methotrexate Plus Vinblastine/Vinorelbine in a Large Series of Patients Affected by Desmoid-Type Fibromatosis , 2017, Cancer journal.

[4]  C. Wittekind,et al.  Neue TNM-Klassifikation der Lungentumoren , 2014, Der Pathologe.

[5]  James Brierley,et al.  Improving the TNM classification: Findings from a 10‐year continuous literature review , 2014, International journal of cancer.

[6]  C. Mussi,et al.  Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm--a position paper from the Italian and the French Sarcoma Group. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  David W. Henry,et al.  Safety and efficacy of high‐dose tamoxifen and sulindac for desmoid tumor in children: Results of a Children's Oncology Group (COG) Phase II Study , 2013, Pediatric blood & cancer.

[8]  J. Habrand,et al.  Desmoid Fibromatosis in Pediatric Patients: Management Based on a Retrospective Analysis of 59 Patients and a Review of the Literature , 2012, Sarcoma.

[9]  A. Ferrari,et al.  Aggressive fibromatosis in children: a changing approach. , 2011, Minerva pediatrica.

[10]  L. Mariani,et al.  Desmoid-Type Fibromatosis: A Front-Line Conservative Approach to Select Patients for Surgical Treatment , 2009, Annals of Surgical Oncology.

[11]  R. Schmelzle,et al.  Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Blay,et al.  Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients. , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[13]  C. Fletcher,et al.  Immunohistochemistry for β‐catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature , 2007 .

[14]  S. Skapek,et al.  Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  B. Meister,et al.  Treatment for soft tissue sarcoma in childhood and adolescence , 2005, Wiener klinische Wochenschrift.

[16]  G. Henze,et al.  Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  L. Sobin,et al.  How to improve the present TNM staging system , 1999, Cancer.

[18]  D. Leung,et al.  Extremity and trunk desmoid tumors , 1999, Cancer.

[19]  M. Gebhardt,et al.  Individualizing management of aggressive fibromatoses. , 1998, International journal of radiation oncology, biology, physics.

[20]  H. Jürgens,et al.  Treatment of soft tissue sarcoma in childhood and adolescence: A report of the german cooperative soft tissue sarcoma study , 1992, Cancer.

[21]  P. Klinge,et al.  Infantile desmoid‐type fibromatosis. Morphological features correlate with biological behaviour , 1991, The Journal of pathology.

[22]  J. Reitamo,et al.  The desmoid syndrome. New aspects in the cause, pathogenesis and treatment of the desmoid tumor. , 1986, American journal of surgery.

[23]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[24]  P. Hohenberger,et al.  Management of sporadic desmoid-type fibromatosis: a European consensus approach based on patients' and professionals' expertise - a sarcoma patients EuroNet and European Organisation for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group initiative. , 2015, European journal of cancer.

[25]  J. Coindre,et al.  [Fourth edition of WHO classification tumours of soft tissue]. , 2015, Annales de pathologie.

[26]  J. Coindre,et al.  [Fourth edition of WHO classification tumours of soft tissue]. , 2015, Annales de pathologie.

[27]  M. Hameed,et al.  Desmoid fibromatosis in children and adolescents: a conservative approach to management. , 2013, Journal of pediatric surgery.

[28]  J. Blay,et al.  Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  A. Zaenglein.  Aggressive Fibromatosis in Children and Adolescents: The Italian Experience , 2011 .

[30]  C. Fletcher,et al.  Immunohistochemistry for beta-catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature. , 2007, Histopathology.

[31]  R. West,et al.  Nuclear beta-catenin in mesenchymal tumors , 2005, Modern Pathology.